# Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine

> **NCT04829747** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 3 (actual)

## Conditions studied

- Chronic Migraine

## Interventions

- **DRUG:** Atogepant

## Key facts

- **NCT ID:** NCT04829747
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-02
- **Primary completion:** 2022-01-20
- **Final completion:** 2022-01-20
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04829747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04829747, "Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04829747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*